vs
Side-by-side financial comparison of NexPoint Real Estate Finance, Inc. (NREF) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
NexPoint Real Estate Finance, Inc. is the larger business by last-quarter revenue ($11.1M vs $9.1M, roughly 1.2× Protalix BioTherapeutics, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -60.3%, a 277.0% gap on every dollar of revenue. On growth, NexPoint Real Estate Finance, Inc. posted the faster year-over-year revenue change (-48.8% vs -49.9%).
NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
NREF vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.1M | $9.1M |
| Net Profit | $24.0M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | — | -51.1% |
| Net Margin | 216.6% | -60.3% |
| Revenue YoY | -48.8% | -49.9% |
| Net Profit YoY | 58.7% | -184.8% |
| EPS (diluted) | $0.47 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.1M | $9.1M | ||
| Q3 25 | $12.5M | $17.9M | ||
| Q2 25 | $12.1M | $15.7M | ||
| Q1 25 | $11.5M | $10.1M | ||
| Q4 24 | $21.7M | $18.2M | ||
| Q3 24 | $12.5M | $18.0M | ||
| Q2 24 | $6.7M | $13.5M | ||
| Q1 24 | $-12.8M | — |
| Q4 25 | $24.0M | $-5.5M | ||
| Q3 25 | $50.9M | $2.4M | ||
| Q2 25 | $22.3M | $164.0K | ||
| Q1 25 | $26.0M | $-3.6M | ||
| Q4 24 | $15.2M | $6.5M | ||
| Q3 24 | $23.3M | $3.2M | ||
| Q2 24 | $12.1M | $-2.2M | ||
| Q1 24 | $-14.6M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | — | — |
| Q4 25 | 216.6% | -60.3% | ||
| Q3 25 | 407.0% | 13.2% | ||
| Q2 25 | 184.5% | 1.0% | ||
| Q1 25 | 225.6% | -35.8% | ||
| Q4 24 | 69.9% | 35.6% | ||
| Q3 24 | 186.4% | 18.0% | ||
| Q2 24 | 179.7% | -16.4% | ||
| Q1 24 | 114.3% | — |
| Q4 25 | $0.47 | $-0.06 | ||
| Q3 25 | $1.14 | $0.03 | ||
| Q2 25 | $0.54 | $0.00 | ||
| Q1 25 | $0.70 | $-0.05 | ||
| Q4 24 | $0.71 | $0.10 | ||
| Q3 24 | $0.74 | $0.03 | ||
| Q2 24 | $0.40 | $-0.03 | ||
| Q1 24 | $-0.83 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.1M | $14.7M |
| Total DebtLower is stronger | $771.2M | — |
| Stockholders' EquityBook value | $388.0M | $48.2M |
| Total Assets | $5.3B | $82.3M |
| Debt / EquityLower = less leverage | 1.99× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.1M | $14.7M | ||
| Q3 25 | $17.9M | $13.6M | ||
| Q2 25 | $9.1M | $17.9M | ||
| Q1 25 | $19.2M | $19.5M | ||
| Q4 24 | $3.9M | $19.8M | ||
| Q3 24 | $34.7M | $27.4M | ||
| Q2 24 | $4.3M | $23.4M | ||
| Q1 24 | $13.5M | — |
| Q4 25 | $771.2M | — | ||
| Q3 25 | $720.9M | — | ||
| Q2 25 | $815.6M | — | ||
| Q1 25 | $831.5M | — | ||
| Q4 24 | $799.3M | — | ||
| Q3 24 | $815.5M | — | ||
| Q2 24 | $861.0M | — | ||
| Q1 24 | $843.3M | — |
| Q4 25 | $388.0M | $48.2M | ||
| Q3 25 | $375.4M | $52.9M | ||
| Q2 25 | $348.2M | $49.9M | ||
| Q1 25 | $343.7M | $45.2M | ||
| Q4 24 | $336.5M | $43.2M | ||
| Q3 24 | $335.8M | $32.4M | ||
| Q2 24 | $327.5M | $28.6M | ||
| Q1 24 | $327.1M | — |
| Q4 25 | $5.3B | $82.3M | ||
| Q3 25 | $5.3B | $82.3M | ||
| Q2 25 | $5.4B | $78.5M | ||
| Q1 25 | $5.4B | $73.9M | ||
| Q4 24 | $5.4B | $73.4M | ||
| Q3 24 | $5.7B | $61.6M | ||
| Q2 24 | $6.6B | $91.5M | ||
| Q1 24 | $7.1B | — |
| Q4 25 | 1.99× | — | ||
| Q3 25 | 1.92× | — | ||
| Q2 25 | 2.34× | — | ||
| Q1 25 | 2.42× | — | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 2.43× | — | ||
| Q2 24 | 2.63× | — | ||
| Q1 24 | 2.58× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.5M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | -0.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.5M | $2.0M | ||
| Q3 25 | $8.1M | $-3.7M | ||
| Q2 25 | $3.3M | $-5.2M | ||
| Q1 25 | $16.0M | $-5.1M | ||
| Q4 24 | $4.4M | $4.0M | ||
| Q3 24 | $14.7M | $4.1M | ||
| Q2 24 | $-7.5M | $-3.6M | ||
| Q1 24 | $17.7M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | -0.19× | — | ||
| Q3 25 | 0.16× | -1.58× | ||
| Q2 25 | 0.15× | -31.91× | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | 0.29× | 0.61× | ||
| Q3 24 | 0.63× | 1.27× | ||
| Q2 24 | -0.62× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NREF
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
